China News Service, Wuhan, February 28 (Reporter Xu Jinbo) The first batch of inactivated vaccines for the novel coronavirus produced by the Wuhan Institute of Biological Products of China National Pharmaceutical Group Co., Ltd. was dispatched from the Wuhan Institute of Biological Products on the 28th.

This is not only the second new crown vaccine approved for conditional marketing by China Biotech, but also the third inactivated vaccine approved for marketing conditionally in China.

  As the lead unit on February 1st last year, China Biotech won the emergency approval of the key special "2019-nCoV inactivated vaccine" project of the Ministry of Science and Technology National Key Research and Development Program "Public Safety Risk Prevention and Control and Emergency Technology and Equipment". The Institute of Biological Products and the Wuhan Institute of Virology of the Chinese Academy of Sciences quickly started cooperation and quickly launched the research and development of new coronavirus inactivated vaccines. The research team has successively overcome vaccine strain screening, establishment of virus seed bank, antibody preparation and identification, establishment of detection methods, compatibility and A series of key technologies for the development, production and quality control of new crown vaccines, including formula screening and production process research, determined the process technology route and product quality attributes, and quickly carried out and completed animal experiments and safety and effectiveness evaluations.

The picture shows the inauguration of the Central China Biological Industry Base. Photo by Xu Jinbo

  On April 12, 2020, the Wuhan Institute of Biological Products of China Biosciences obtained the world's first clinical approval for an inactivated new coronavirus vaccine and simultaneously carried out I/II clinical trials. The statistical results showed that the safety after vaccination was good; different procedures, different After dose vaccination, all vaccinators in the vaccine group produced high-titer antibodies.

On June 23, the UAE Minister of Health issued a clinical trial approval document to China Biotech, marking the official launch of the world's first international clinical trial (Phase III) of the new crown inactivated vaccine.

On June 30, the first batch of the vaccine was put into emergency use, and emergency vaccinations were successively carried out for specific populations in China.

  On February 25 this year, the National Medical Products Administration, in accordance with the relevant provisions of the Vaccine Management Law and the Drug Management Law, formally approved the new type of coronavirus of Sinopharm China Biologics Wuhan Institute of Biological Products Co., Ltd. in accordance with the special drug approval procedures. Application for registration of inactivated virus vaccine (Vero cell).

  On the 28th, the first batch of "Made in Wuhan" new coronavirus inactivated vaccines approved for marketing departed from the Wuhan Institute of Biological Products.

The Institute of Biological Products has built a biosafety workshop for the new crown inactivated vaccine. After inspection and certification by the relevant state departments, it has been put into large-scale production, with an annual output of 100 million doses.

  On the same day, Sinopharm's China Biological Central Industrial Base was inaugurated simultaneously. The base is centered on the Wuhan Institute of Biological Products project, focusing on the production of vaccines, blood preparations and therapeutic biological drugs, and will become a modern biological drug industrialization base. The relevant person in charge of Wuhan said that the industrial base has played an important role in promoting the development of a trillion-level large health industry cluster in Wuhan, and promoting Wuhan's post-epidemic recovery and rebirth.